» Articles » PMID: 29988891

Melatonin in Drug Addiction and Addiction Management: Exploring an Evolving Multidimensional Relationship

Overview
Specialty Psychiatry
Date 2018 Jul 11
PMID 29988891
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Melatonin is a pleiotropic signalling molecule that regulates several physiological functions, and synchronises biological rhythms. Recent evidences are beginning to reveal that a dysregulation of endogenous melatonin rhythm or action may play a larger role in the aetiology and behavioural expression of drug addiction, than was previously considered. Also, the findings from a number of animal studies suggest that exogenous melatonin supplementation and therapeutic manipulation of melatonin/melatonin receptor interactions may be beneficial in the management of behavioural manifestations of drug addiction. However, repeated exogenous melatonin administration may cause a disruption of its endogenous rhythm and be associated with potential drawbacks that might limit its usefulness. In this review, we examine the roles of melatonin and its receptors in addictive behaviours; discussing how our understanding of melatonin's modulatory effects on the brain rewards system and crucial neurotransmitters such as dopamine has evolved over the years. Possible indications(s) for melatonergic agents in addiction management, and how manipulations of the endogenous melatonin system may be of benefit are also discussed. Finally, the potential impediments to application of melatonin in the management of addictive behaviours are considered.

Citing Articles

Neurotransmitters crosstalk and regulation in the reward circuit of subjects with behavioral addiction.

Peng Z, Jia Q, Mao J, Luo X, Huang A, Zheng H Front Psychiatry. 2025; 15:1439727.

PMID: 39876994 PMC: 11773674. DOI: 10.3389/fpsyt.2024.1439727.


Exploring the association between melatonin and nicotine dependence (Review).

Georgakopoulou V, Sklapani P, Trakas N, Reiter R, Spandidos D Int J Mol Med. 2024; 54(4).

PMID: 39092582 PMC: 11315657. DOI: 10.3892/ijmm.2024.5406.


Exploring the potential use of melatonin as a modulator of tramadol-induced rewarding effects in rats.

Hakami A, Alghamdi B, Alshehri F Front Pharmacol. 2024; 15:1373746.

PMID: 38738177 PMC: 11082292. DOI: 10.3389/fphar.2024.1373746.


Mechanistic Insights and Potential Therapeutic Implications of NRF2 in Diabetic Encephalopathy.

Cheng X, Tan Y, Li H, Zhang Z, Hui S, Zhang Z Mol Neurobiol. 2024; 61(10):8253-8278.

PMID: 38483656 DOI: 10.1007/s12035-024-04097-5.


Alterations of Gut-Derived Melatonin in Neurobehavioral Impairments Caused by Zinc Oxide Nanoparticles.

Yang C, Lu Z, Xia Y, Zhang J, Zou Z, Chen C Int J Nanomedicine. 2023; 18:1899-1914.

PMID: 37057188 PMC: 10088905. DOI: 10.2147/IJN.S386240.


References
1.
Mohawk J, Pezuk P, Menaker M . Methamphetamine and dopamine receptor D1 regulate entrainment of murine circadian oscillators. PLoS One. 2013; 8(4):e62463. PMC: 3633847. DOI: 10.1371/journal.pone.0062463. View

2.
Jaffe J, Cascella N, Kumor K, Sherer M . Cocaine-induced cocaine craving. Psychopharmacology (Berl). 1989; 97(1):59-64. DOI: 10.1007/BF00443414. View

3.
Uz T, Arslan A, Kurtuncu M, Imbesi M, Akhisaroglu M, Dwivedi Y . The regional and cellular expression profile of the melatonin receptor MT1 in the central dopaminergic system. Brain Res Mol Brain Res. 2005; 136(1-2):45-53. DOI: 10.1016/j.molbrainres.2005.01.002. View

4.
Jadidi N, Nakhaee N . Etiology of drug abuse: a narrative analysis. J Addict. 2014; 2014:352835. PMC: 4160618. DOI: 10.1155/2014/352835. View

5.
Noori H, Spanagel R, Hansson A . Neurocircuitry for modeling drug effects. Addict Biol. 2012; 17(5):827-64. DOI: 10.1111/j.1369-1600.2012.00485.x. View